BioMed Research International / 2019 / Article / Tab 1

Review Article

Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery

Table 1

Comparison of performance, strengths and weaknesses of promising sequencing platforms.

Platform\instrumentThroughput range (Gb)Read length (bp)StrengthWeakness

Sanger sequencing
ABI 3500/37300.0003Up to 1 kbRead accuracy and lengthCost and throughput

Illumina
MiniSeq1.7–7.51 × 75 to 2 × 150Low initial investmentRun and read length
MiSeq0.3–151 × 36 to 2 × 300Read length, scalabilityRun length
NextSeq10–1201 × 75 to 2 × 150ThroughputRun and read length
HiSeq (2500)10–10001 × 50 to 2 × 250Read accuracy, throughput, low per sample costHigh initial investment, run length
HiSeq 3000/HiSeq 4000105–15002 × 50 to 2 × 150Read accuracy, throughput, low per sample costHigh initial investment, run and read length
NovaSeq 5000/60002000–60002 × 50 to 2 × 150Read accuracy, throughput, low per sample costHigh initial investment, run and read length

IonTorrent
PGM0.08–2Up to 400Read length, speedThroughput, homopolymers
S50.6–15Up to 400Read length, speed, scalabilityHomopolymers
Proton10–15Up to 200Speed, throughputHomopolymers
Ion GeneStudio S5 prime System (ion 550″ chip)10–50Up to 200 (2 runs in one day)Read length, speed, scalabilityHomopolymers

Oxford nanopore
MInION0.1–1Up to 100 kbRead length, portabilityHigh error rate, run length, low throughput
GridION X550–100Up to 1000 kbThe GridION X5 offers real time, long-read, high-fidelity DNA and RNA sequencing.High error rate
Pacific BioSciences
PacBio RSII0.5–1Up to 60 kb(Average 10 kb, N50 20 kb)Read length, speedHigh error rate and initial investment, low throughput
Sequel5–10Up to 60 kb(Average 10 kb, N50 20 kb)Read length, speedHigh error rate
Sequel II9–13Up to 160 GbRead length, speedInitial investment

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.